Background
Magnolia Medical Technologies filed an inter partes review petition challenging a Kurin patent after losing a jury trial on the same patent. The petition sought to relitigate validity issues that had been — or could have been — raised during the completed trial. The case arrived at a moment when USPTO Director John Squires has been actively reshaping PTAB institution practices through a series of high-profile discretionary denials.
Director Squires exercised his discretionary authority to deny institution, designating the decision as precedential — his latest in a string of precedential opinions that collectively articulate a new framework for when AIA proceedings should and should not be instituted.
The Court’s Holding
The Director denied institution and articulated six principles governing the exercise of discretion in AIA proceedings. The central holding was blunt: the IPR system was “designed as an alternative to litigation, not as a tool for ‘litigation leverage.'” The Director found that Magnolia was attempting to obtain “a second bite at the apple” after losing at trial, and that “the lack of a jury verdict as to anticipation or obviousness in the now-completed jury trial does not entitle Petitioner to re-litigate the same issues at the Office.”
The decision also highlighted a striking concentration in IPR filings: the top ten petitioners have filed approximately 1,900 petitions — roughly equal to the number filed by the next 70 petitioners combined. Director Squires cited this statistic to support a principle that the PTAB should consider whether a petition is being used for genuine validity challenges or as a strategic weapon by companies with disproportionate resources.
The six principles include treating AIA proceedings as litigation alternatives rather than harassment tools, preventing serial petitions after losses in other forums, scrutinizing inconsistent positions across forums, considering the petitioner’s market position and whether the petition targets a small business, and prioritizing public interest over private competitive advantage.
Key Takeaways
- Post-trial IPR petitions face steep obstacles. Filing an IPR after losing at trial will be presumptively denied under the Director’s framework — even if the specific validity grounds differ from those raised at trial.
- Director Squires is building a body of precedential IPR-reform case law. This decision is part of a broader pattern of precedential opinions that collectively restrict PTAB access for serial petitioners and repeat challengers.
- Market-dominant petitioners face heightened scrutiny. The decision’s emphasis on filing concentration signals that the Director views some companies’ IPR strategies as systemically problematic.
Why It Matters
This precedential decision continues Director Squires’ transformation of PTAB institution practice. For patent holders — particularly smaller companies — the decision offers significant protection against well-resourced competitors who previously could file multiple IPR challenges as a litigation strategy even after losing in court. For major technology companies that have historically been among the heaviest IPR filers, the decision signals that their petitions will receive more searching review under a framework that explicitly considers whether the petition serves the public interest or merely provides “litigation leverage.” The cumulative effect of these precedential decisions is a PTAB that is increasingly reluctant to serve as a forum for relitigating issues that have been or could have been resolved in district court.